Mice with K-ras mutant lung tumors treated with anti-IL-6 antibodies have shown an overall reduction in tumor burden and a shift to a TME with a less proliferative and a less protumor inflammatory context: fewer Th17 cells, fewer Tregs, and more M1-type polarization (62). Here, IL6 is linked to neoplasm.